{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:25:32Z","timestamp":1792661132059,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.beem.2007.01.007","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T07:00:49Z","timestamp":1174546849000},"page":"111-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Peptide receptor radionuclide therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Flavio","family":"Forrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelf","family":"Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik J.","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2007.01.007_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.beem.2007.01.007_bib2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib3","first-page":"3882","article-title":"Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location","volume":"85","author":"Reubi","year":"2000","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2007.01.007_bib4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib5","first-page":"1704","article-title":"Peptide receptor imaging and therapy","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib6","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","article-title":"Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data","volume":"28","author":"Hofmann","year":"2001","journal-title":"European Journal of Nuclear Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib7","first-page":"172S","article-title":"(68)Ga-labeled peptides in tumor imaging","volume":"46","author":"Maecke","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beem.2007.01.007_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00259-002-1012-1","article-title":"PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide","volume":"30","author":"Wester","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib10","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotid. State of the art and perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"The Quarterly Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib12","first-page":"1","article-title":"Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors","volume":"44","author":"Buscombe","year":"2003","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-dPhe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beem.2007.01.007_bib15","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib16","first-page":"703","article-title":"Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors","volume":"26","author":"Forrer","year":"2006","journal-title":"Anticancer Research"},{"key":"10.1016\/j.beem.2007.01.007_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","article-title":"In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial","volume":"32","author":"Virgolini","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00761-004-0771-7","article-title":"Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga","volume":"10","author":"Baum","year":"2004","journal-title":"Der Onkologe"},{"key":"10.1016\/j.beem.2007.01.007_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"supplement 2","key":"10.1016\/j.beem.2007.01.007_bib21","first-page":"S231","article-title":"Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib22","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabelled somatostatin analog [177Lu-DOTAO,Tyr3]octreotate in patients with endocrine gastro entero pancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beem.2007.01.007_bib23","first-page":"1310","article-title":"Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC","volume":"46","author":"Forrer","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-d-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.beem.2007.01.007_bib25","first-page":"1260","article-title":"A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu","volume":"45","author":"Konijnenberg","year":"2004","journal-title":"Journal of Nuclear Medicine"},{"issue":"supplement 2","key":"10.1016\/j.beem.2007.01.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000049157","article-title":"Somatostatin analogs for cancer treatment and diagnosis: an overview","volume":"47","author":"Scarpignato","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.beem.2007.01.007_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0026-0495(96)90077-3","article-title":"Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels","volume":"45","author":"Reubi","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2007.01.007_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/mcne.1993.1040","article-title":"Somatostatin receptors: orphan that found family and function","volume":"4","author":"Bruno","year":"1993","journal-title":"Molecular and Cellular Neurosciences"},{"key":"10.1016\/j.beem.2007.01.007_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1006\/bbrc.1993.2122","article-title":"Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype","volume":"195","author":"Yamada","year":"1993","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.beem.2007.01.007_bib32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","article-title":"Endocrine tumours of the pancreas","volume":"19","author":"Oberg","year":"2005","journal-title":"Best Practice and Research. Clinical Gastroenterology"},{"key":"10.1016\/j.beem.2007.01.007_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","article-title":"Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver","volume":"81","author":"Slooter","year":"1999","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.beem.2007.01.007_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0969-8051(93)90137-J","article-title":"The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators","volume":"20","author":"Mardirossian","year":"1993","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.beem.2007.01.007_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1039\/b309961j","article-title":"The role of coordination chemistry in the development of target-specific radiopharmaceuticals","volume":"33","author":"Liu","year":"2004","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/j.beem.2007.01.007_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/BF00879669","article-title":"DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy","volume":"24","author":"Otte","year":"1997","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snuc.2002.31563","article-title":"Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group","volume":"32","author":"Chinol","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-d-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.beem.2007.01.007_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","article-title":"Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours","volume":"31","author":"Bodei","year":"2004","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"supplement 2","key":"10.1016\/j.beem.2007.01.007_bib41","first-page":"232","article-title":"Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0,Tyr3)octreotide in patients with somatostatin receptor positive tumours","volume":"30","author":"Valkema","year":"2003","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"de Jong","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"issue":"supplement 2","key":"10.1016\/j.beem.2007.01.007_bib44","first-page":"S238","article-title":"Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors","volume":"31","author":"Baum","year":"2004","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/02841868709113712","article-title":"Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin \u2013 alone or in combination with 5\u2013FU","volume":"26","author":"Oberg","year":"1987","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"key":"10.1016\/j.beem.2007.01.007_bib47","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beem.2007.01.007_bib48","first-page":"327","article-title":"Combination chemotherapy trials in metastatic crcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clinical Trials"},{"key":"10.1016\/j.beem.2007.01.007_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib50","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00259-004-1553-6","article-title":"A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours","volume":"31","author":"Forrer","year":"2004","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib51","first-page":"1168","article-title":"Inhomogeneous localization of radioactivity in the human\u00a0kidney after injection of [(111)In-DTPA]octreotide","volume":"45","author":"De Jong","year":"2004","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib52","first-page":"1696","article-title":"Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide","volume":"46","author":"de Jong","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"issue":"12 supplement","key":"10.1016\/j.beem.2007.01.007_bib53","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2591::AID-CNCR35>3.0.CO;2-5","article-title":"Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry","volume":"80","author":"Behr","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2007.01.007_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib55","first-page":"528","article-title":"Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats","volume":"47","author":"van Eerd","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib56","first-page":"432","article-title":"Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin","volume":"47","author":"Vegt","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib57","first-page":"43","article-title":"Amifostine is most promising in protecting renal function during radionuclide therapy with [Lu-177-DOTA0,Tyr3]octreotate","volume":"47","author":"Forrer","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib58","doi-asserted-by":"crossref","unstructured":"Rolleman EJ, Forrer F Bernard B, Bijster M, et\u00a0al. Amifostine protects rat kidneys in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging 2006 Dec 5 [Epub ahead of print].","DOI":"10.1007\/s00259-006-0291-3"},{"key":"10.1016\/j.beem.2007.01.007_bib59","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.beem.2007.01.007_bib60","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","article-title":"End-stage renal disease after treatment with 90Y-DOTATOC","volume":"28","author":"Cybulla","year":"2001","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib61","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/16.5.1082","article-title":"Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma","volume":"16","author":"Stoffel","year":"2001","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.beem.2007.01.007_bib62","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose\u2013effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2007.01.007_bib64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib65","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0,Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib66","first-page":"92S","article-title":"Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs","volume":"46","author":"Pauwels","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib67","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/108497803322287664","article-title":"Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases","volume":"18","author":"Bushnell","year":"2003","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"key":"10.1016\/j.beem.2007.01.007_bib68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1067\/j.cpsurg.2006.03.002","article-title":"Carcinoid tumors","volume":"43","author":"Raut","year":"2006","journal-title":"Current Problems in Surgery"},{"key":"10.1016\/j.beem.2007.01.007_bib69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases","volume":"26","author":"Berber","year":"2002","journal-title":"World Journal of Surgery"},{"key":"10.1016\/j.beem.2007.01.007_bib70","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","article-title":"Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors","volume":"26","author":"Hellman","year":"2002","journal-title":"World Journal of Surgery"},{"key":"10.1016\/j.beem.2007.01.007_bib71","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","article-title":"Therapeutic options for gastrointestinal carcinoids","volume":"4","author":"Modlin","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"supplement 2","key":"10.1016\/j.beem.2007.01.007_bib72","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beem.2007.01.007_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.amjsurg.2004.01.019","article-title":"Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors","volume":"187","author":"Toth-Fejel","year":"2004","journal-title":"American Journal of Surgery"},{"key":"10.1016\/j.beem.2007.01.007_bib74","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beem.2007.01.007_bib75","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.1136.11.3","article-title":"Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy","volume":"11","author":"Ginj","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beem.2007.01.007_bib76","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","article-title":"Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities","volume":"30","author":"Breeman","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2007.01.007_bib77","first-page":"3652","article-title":"Differential regulation of somatostatin receptor type 2 (sst\u00a02) expression in AR4-2J tumor cells implanted into mice during octreotide treatment","volume":"59","author":"Froidevaux","year":"1999","journal-title":"Cancer Research"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib78","first-page":"13S","article-title":"Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs","volume":"46","author":"de Jong","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib79","first-page":"807","article-title":"Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production","volume":"47","author":"Uusijarvi","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib80","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-05-1264","article-title":"213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model","volume":"12","author":"Norenberg","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beem.2007.01.007_bib81","first-page":"2472","article-title":"A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer","volume":"9","author":"van Putten","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beem.2007.01.007_bib82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(00)01471-1","article-title":"Low-dose hypersensitivity: current status and possible mechanisms","volume":"49","author":"Joiner","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.beem.2007.01.007_bib83","doi-asserted-by":"crossref","first-page":"49624","DOI":"10.1074\/jbc.M409600200","article-title":"Evasion of early cellular response mechanisms following low level radiation-induced DNA damage","volume":"279","author":"Collis","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"supplement 1","key":"10.1016\/j.beem.2007.01.007_bib84","first-page":"67S","article-title":"Candidates for peptide receptor radiotherapy today and in the future","volume":"46","author":"Reubi","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2007.01.007_bib85","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0969-8051(03)00116-1","article-title":"Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update","volume":"30","author":"Smith","year":"2003","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.beem.2007.01.007_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/bip.10356","article-title":"Cholecystokinin-B (CCK-B)\/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies","volume":"66","author":"Behe","year":"2002","journal-title":"Biopolymers"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X07000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X07000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:36:34Z","timestamp":1761496594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X07000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1521690X07000085"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2007.01.007","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide receptor radionuclide therapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2007.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}